Media coverage about BIO-TECHNE (NASDAQ:TECH) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BIO-TECHNE earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.184647465234 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
- BidaskClub Upgrades BIO-TECHNE (TECH) to “Strong-Buy” (americanbankingnews.com)
- Bio-Techne introduces MimEX GI, an accessible 3-D cell culturing platform for the GI tract (pharmabiz.com)
- 10 Growth Stocks for Long-Term Investors (finance.yahoo.com)
- Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract (finance.yahoo.com)
A number of equities analysts have recently issued reports on TECH shares. Zacks Investment Research downgraded shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. BidaskClub cut shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Leerink Swann reaffirmed a “buy” rating on shares of BIO-TECHNE in a research report on Tuesday, December 5th. Robert W. Baird reaffirmed a “buy” rating and set a $154.00 price target on shares of BIO-TECHNE in a research report on Thursday, January 18th. Finally, Craig Hallum restated a “buy” rating and issued a $160.00 price target (up previously from $140.00) on shares of BIO-TECHNE in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $148.60.
BIO-TECHNE (NASDAQ:TECH) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.10. The firm had revenue of $154.15 million for the quarter, compared to the consensus estimate of $145.93 million. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. equities research analysts anticipate that BIO-TECHNE will post 4.01 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 2nd. Stockholders of record on Friday, February 16th were issued a $0.32 dividend. The ex-dividend date of this dividend was Thursday, February 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.86%. BIO-TECHNE’s dividend payout ratio is 41.97%.
In related news, Director Charles A. Dinarello sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total value of $680,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.40% of the company’s stock.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.